assignment
Recruiting

Phase 3b Evaluation of Efficacy and Safety of Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Patients

Trial ID
2024-514641-12-00
Protocol
VX21-CTX001-161

Register record, history and transparency: CTIS.eu

Trial statistics

science
4
test molecules
location_city
2
research sites
public
2
countries
medical_information
2
diseases
person_search
2
investigators

Diseases & Conditions

Sickle cell anaemiaThalassaemia beta

Objectives

The primary objective of this Phase 3b study is to assess **HbF** levels over time following a single dose of autologous CRISPR/Cas9 modified CD34+ human hematopoietic stem and progenitor cells (CTX001) in adolescent and adult subjects with either transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). This is clinically relevant as increased HbF levels can ameliorate the symptoms and reduce the complications associated with these hematological disorders.

Secondary objectives include:

  • Evaluating the efficacy and safety of a single dose of CTX001 in adolescent and adult subjects with either TDT or severe SCD.
  • Assessing the effects of CTX001 infusion on disease-specific events and clinical status.
  • Quantifying gene editing efficiency.

Participants

The clinical trial involves a total of **20 participants** diagnosed with either **transfusion-dependent β-thalassemia (TDT)** or severe **sickle cell disease (SCD)**. The study population includes both male and female subjects, with an age range encompassing adolescents and adults. Participants were selected based on their eligibility for autologous stem cell transplant, as determined by the investigator's judgment. The trial does not include a vulnerable population. Participants with TDT must have a documented diagnosis of homozygous β-thalassemia or compound heterozygous β-thalassemia, with a history of significant red blood cell transfusions. Those with SCD must have a documented SCD genotype and a history of at least two severe vaso-occlusive crisis events per year in the two years preceding enrollment. The trial does not specify any particular lifestyle considerations such as diet or physical activity.

Plans and Procedures

The clinical trial is designed to evaluate the efficacy and safety of a single dose of **exagamglogene autotemcel** in subjects with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). This is a Phase 3b, randomized, double-blind, controlled study. The trial aims to assess hemoglobin F (HbF) levels over time following the administration of autologous CRISPR/Cas9 modified CD34+ human hematopoietic stem and progenitor cells (CTX001). The study is expected to conclude by July 2025, with recruitment having commenced in July 2022.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on specific criteria, such as a documented diagnosis of TDT or SCD and a history of transfusions or vaso-occlusive crises. Following the screening, eligible participants will receive the investigational product and attend follow-up visits to monitor safety and efficacy outcomes. These visits will include assessments of HbF and hemoglobin levels, adverse events, and engraftment metrics. The end-of-study visit will mark the completion of the trial for each participant, with evaluations continuing up to 12 months post-infusion.

The expected duration of participant involvement is approximately 12 months, with conditions for early termination including significant adverse events or withdrawal of consent. The primary endpoint focuses on HbF and hemoglobin levels over time, starting 60 days after the last red blood cell transfusion. Secondary endpoints include safety and tolerability assessments, reduction in transfusion volume, and genetic modification presence in blood and bone marrow. The trial involves the use of auxiliary products such as **filgrastim**, **busulfan**, and **plerixafor** to support the conditioning and mobilization processes. Participants will receive these products via subcutaneous or intravenous routes as per protocol specifications.

Treatment

The clinical trial involves the administration of **Filgrastim**, a **solution for injection/infusion**. Filgrastim is a protein-based therapeutic agent used to stimulate the production of white blood cells. It is administered via **subcutaneous injection** at a dosage of up to 10 µg/kg per day, with a maximum total dose of 60 µg/kg over a treatment period of up to 6 days. Participant compliance with the dosing schedule is monitored throughout the trial.

**Exagamglogene autotemcel**, marketed as Casgevy, is a **dispersion for infusion** used in this study. It is an autologous cell therapy product containing CD34+ hematopoietic stem cells modified using CRISPR-Cas9 technology to disrupt the BCL11A gene, thereby enhancing fetal hemoglobin production. The product is administered via **intravenous infusion** at a concentration of 4 - 13 x 10^6 cells/mL, with a maximum total dose of 20 units over a single treatment period. This product is designated as an orphan drug for the treatment of transfusion-dependent β-thalassemia and severe sickle cell disease.

**Busulfan** is included in the trial as a **concentrate for solution for infusion**. It is a chemotherapeutic agent used to prepare patients for stem cell transplantation. Busulfan is administered intravenously, with a maximum daily dose of 4.4 mg/kg and a total dose of 17.6 mg/kg over a treatment period of up to 4 days. The administration schedule is carefully monitored to ensure participant safety and compliance.

**Plerixafor** is utilized as a **solution for injection** in this study. It is a biological agent used to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent transplantation. Plerixafor is administered via **subcutaneous injection** at a dosage of 0.24 mg/kg per day, with a maximum total dose of 0.96 mg/kg over a treatment period of up to 4 days. Compliance with the administration schedule is closely monitored to optimize the mobilization process.

Efficacy

The efficacy of the clinical trial will be assessed primarily by measuring **HbF** and Hb levels over time. This evaluation will commence 60 days after the last red blood cell (RBC) transfusion, which is administered for post-transplant support or disease management. Secondary endpoints include the safety and tolerability of CTX001, assessed through adverse events, clinical laboratory values, neutrophil and platelet engraftment, transplant-related mortality, and all-cause mortality. Additionally, the trial will evaluate the relative reduction from baseline in the annualized volume of RBC transfusions and the proportion of alleles with intended genetic modification present in peripheral blood and CD34+ cells of the bone marrow over time.

For participants with transfusion-dependent **β-Thalassemia** (TDT), the duration of being transfusion-free will be monitored. For those with severe **Sickle Cell Disease** (SCD), the trial will assess the relative reduction from baseline in the annualized rate of severe vaso-occlusive crises (VOCs), inpatient hospitalizations for severe VOCs, and the duration of hospitalization for severe VOCs, all up to 12 months after CTX001 infusion. The evaluation for these parameters will also start 60 days after the last RBC transfusion for post-transplant support or SCD disease management. Furthermore, the trial will measure the relative reduction from baseline in markers of hemolysis up to 12 months post-infusion.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Participants with TDT and SCD: Eligible for autologous stem cell transplant as per investigator's judgment.
  • Participants with TDT: Diagnosis of TDT as defined by: Documented homozygous β-thalassemia or compound heterozygous β-thalassemia including β-thalassemia/hemoglobin E (HbE). Participants can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning History of at least 100 milliliter (mL)/kilograms (kg)/year or 10 units/year of packed red blood cells (RBC) transfusions in the prior 2 years before signing the consent or the last rescreening for patients going through re-screening
  • Participants with SCD: Diagnosis of severe SCD as defined by: Documented SCD genotypes History of at least two severe VOCs events per year for the previous two years prior to enrollment
cancel

Exclusion Criteria

  • Participants with TDT and SCD: A willing and healthy 10/10 human leukocyte antigen (HLA)-matched related donor is available per investigator's judgement Prior hematopoietic stem cell transplant (HSCT) Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator
  • Participants with TDT: Participants with associated α-thalassemia and >1 alpha deletion, or alpha multiplications Participants with sickle cell β-thalassemia variant
  • Participants with SCD: History of untreated moyamoya syndrome or presence of moyamoya syndrome at screening

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Germany GermanyRecruiting01 Jul 20222
Italy ItalyRecruiting01 Jul 20224

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
PLERIXAFOR
Other—SUBCUTANEOUS INJECTION0.244SUB28849
Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion
TestDISPERSION FOR INFUSIONINTRAVENOUS USE201PRD11151564
BUSULFAN
Other—INTRAVENOUS USE4.44SUB05993MIG
FILGRASTIM
Other—SUBCUTANEOUS INJECTION106SUB07627MIG

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Filgrastim
33 trials

Also investigated for

Triple negative breast cancer 3Ewing's sarcoma 2Thalassaemia beta 2Acute lymphocytic leukaemia 1
vaccines
Plerixafor
13 trials

Also investigated for

Sickle cell anaemia 4Thalassaemia beta 3Mucopolysaccharidosis I 2Thalassaemia 2
vaccines
Busulfan
29 trials

Also investigated for

Acute myeloid leukaemia 6Sickle cell anaemia 4Myelodysplastic syndrome 3Thalassaemia beta 3
vaccines
Exagamglogene Autotemcel
7 trials

Also investigated for

Sickle cell anaemia 5Thalassaemia 2Thalassaemia beta 2